Just a month after landing a $15 million payday for a deal with Astellas to collaborate on new antibody drug conjugates for cancer, the San Diego-based biotech Ambrx has scored another research pact--reaping another $15 million upfront from Bristol-Myers in exchange for a new oncology partnership.
Fast-moving Celgene has turned to Presage Biosciences to begin testing the potential of cancer drug combinations in animals, paying $5 million upfront to support the research and taking an $8 million equity stake in the up-and-coming biotech.
And in a preview of its R&D showcase, the pharma giant--which spent an industry-leading $9.58 billion on R&D last year--offered a bullish assessment of a slate of experimental therapies it believes can break past the $1 billion annual revenue mark.
The long campaign to beat cancer has become, on many fronts, a cyber war. As Reuters reports, Roche, Eli Lilly and other major outfits in oncology view tech tools as important to understanding the genetic drivers of cancer and their efforts to develop new drugs.
Just weeks after scoring a deal to develop biosimilars with Merck Serono, Dr. Reddy's Laboratories is boasting about the rapid growth in its biosims business.
With Gilead's Quad team deep into a Phase III program aimed at a successor to Atripla, the biotech company has been methodically piecing together a long-term initiative aimed at developing a new
Shares of Boulder, CO-based Array BioPharma ( NASDAQ: ARRY ) spiked 33 percent overnight after the developer announced that it had inked a $467 million oncology pact with Novartis. The deal includes a
Norway's Clavis Pharma has reason to celebrate this morning. The developer has inked a $380 million deal with US-based Clovis Oncology, sending shares up as much as 60 percent, according to Reuters.
Anyone looking for a clue where Pfizer will be spending its R&D money would do well to check out some remarks made yesterday by Andreas Penk, the regional chief of Pfizer's European cancer
Daiichi Sankyo, Japan's third largest pharma company, is on the prowl for new biotech acquisitions in Europe that can help advance its cancer research work. And the hungry pharma player has also